Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment

被引:34
|
作者
Gurkan, Kagan [1 ]
Bilgic, Ayhan [2 ]
Turkoglu, Serhat [2 ]
Kilic, Birim G. [1 ]
Aysev, Ayla [1 ]
Uslu, Runa [1 ]
机构
[1] Ankara Univ, Dept Child & Adolescent Psychiat, Sch Med, TR-06100 Ankara, Turkey
[2] Gulhane Mil Med Acad, Dept Child & Adolescent Psychiat, Ankara, Turkey
关键词
anxiety; attention-deficit hyperactivity disorder (ADHD); children; depression; health-related quality of life; methylphenidate; obsessive-compulsive symptoms; RELIABILITY; PLACEBO; INVENTORY; VALIDITY; PARENT; ADULTS;
D O I
10.1177/0269881109348172
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The current study was designed to investigate the changes that occur in depression, anxiety, obsessive-compulsive symptoms and health-related quality of life during methylphenidate (MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD). Forty-five treatment naive children with ADHD, aged 8-14, were assessed based on self, parent and teacher reports at the baseline and at the end of the first and third month of MPH treatment regarding changes in inattention, hyperactivity, impulsivity, depression, anxiety and obsessive-compulsive symptoms. Changes in the quality of life were also noted. Repeated measures of analysis of variance (ANOVA) tests with Bonferroni corrections were conducted in order to evaluate the data. Symptoms of inattention, hyperactivity and impulsivity were significantly reduced (p < 0.017) following a three-month MPH treatment. There were significant decreases in depression (p = 0.004), trait anxiety (p = 0.000) and checking compulsion symptom scores (p = 0.001). Moreover, parents reported significant improvements in psychosocial (p = 0.001) and total scores (p = 0.009) of quality of life, despite no change in physical health scores (p > 0.05). Children's ratings of quality of life measures showed no significant changes in physical health and psychosocial scores (p > 0.05), while total scores significantly improved (p = 0.001) after the treatment. Over a three-month MPH treatment, depression, trait anxiety and checking compulsion symptoms decreased and quality of life seemed to improve along with those of inattention, hyperactivity and impulsivity.
引用
收藏
页码:1810 / 1818
页数:9
相关论文
共 50 条
  • [41] The Effectiveness of Methylphenidate in the Treatment of Encopresis Independent from Attention-Deficit Hyperactivity Disorder Symptoms
    Akca, Omer Faruk
    Yilmaz, Savas
    PSYCHIATRY INVESTIGATION, 2015, 12 (01) : 150 - 151
  • [42] Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder
    Handen, BL
    Johnson, CR
    Lubetsky, M
    JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2000, 30 (03) : 245 - 255
  • [43] Methylphenidate in the treatment of children and adolescents with bipolar disorder and Attention-Deficit/Hyperactivity disorder
    Findling, Robert L.
    Short, Elizabeth J.
    McNamara, Nora K.
    Demeter, Christine A.
    Stansbrey, Robert J.
    Gracious, Barbara L.
    Whipkey, Resaca
    Manos, Michael J.
    Calabrese, Joseph R.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2007, 46 (11) : 1445 - 1453
  • [44] Efficacy of Methylphenidate Among Children with Autism and Symptoms of Attention-Deficit Hyperactivity Disorder
    Benjamin L. Handen
    Cynthia R. Johnson
    Martin Lubetsky
    Journal of Autism and Developmental Disorders, 2000, 30 : 245 - 255
  • [45] Effects of Methylphenidate and Atomoxetine Treatment on Improvement of Motor Coordination in Children With Attention-Deficit/Hyperactivity Disorder
    Kim, Ju Yeon
    Jung, Eunji
    Lee, Taeyeop
    Park, Kee Jeong
    Joung, Yoo-Sook
    Kim, Hyo-Won
    PSYCHIATRY INVESTIGATION, 2025, 22 (01) : 84 - 92
  • [46] Progression of symptoms in children with attention deficit and hyperactivity disorder in treatment with methylphenidate
    Rodriguez Hernandez, Pedro J.
    Betancort Montesinos, Moises
    Penate Castro, Wenceslao
    MEDICINA-BUENOS AIRES, 2020, 80 : 72 - 75
  • [47] Obsessive-compulsive disorder and attention-deficit/hyperactivity disorder: distinct associations with DNA methylation and genetic variation
    Goodman, Sarah J.
    Burton, Christie L.
    Butcher, Darci T.
    Siu, Michelle T.
    Lemire, Mathieu
    Chater-Diehl, Eric
    Turinsky, Andrei L.
    Brudno, Michael
    Soreni, Noam
    Rosenberg, David
    Fitzgerald, Kate D.
    Hanna, Gregory L.
    Anagnostou, Evdokia
    Arnold, Paul D.
    Crosbie, Jennifer
    Schachar, Russell
    Weksberg, Rosanna
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2020, 12 (01)
  • [48] Influence of Psychopharmacotherapy on the Quality of Life of Children with Attention-Deficit/Hyperactivity Disorder
    Temizsoy, Hanife
    Oezlue-Erkilic, Zeliha
    Ohmann, Susanne
    Sackl-Pammer, Petra
    Popow, Christian
    Akkaya-Kalayci, Tuerkan
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2019, 29 (06) : 419 - 425
  • [49] Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate
    Boesen, Kim
    Gotzsche, Peter C.
    JAMA PSYCHIATRY, 2016, 73 (05) : 533 - 534
  • [50] Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study
    Jafarinia, Morteza
    Mohammadi, Mohammad-Reza
    Modabbernia, Amirhossein
    Ashrafi, Mandana
    Khajavi, Danial
    Tabrizi, Mina
    Yadegari, Noorollah
    Akhondzadeh, Shahin
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2012, 27 (04) : 411 - 418